EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance

Albano Cáceres-Verschae iD, Petra Hååg iD, Sofia Joelsson iD, Per Hydbring iD, Bo Franzén iD, Ákos Végvári iD, Inger Johanne Z Eide iD, Nupur Agarwal iD, Siddharth Sourabh Sahu iD, Fredrik Stridfeldt iD, Luigi De Petris iD, Apurba Dev iD und 4 weitere

Journal of Extracellular Vesicles · 2026-01 · 15 (1)

DOI: 10.1002/jev2.70219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 25.01.2026. Verfasst von Albano Cáceres-Verschae und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erling-Perssons Stiftelse, Forskning Utbildning och Utveckilng, Karolinska Hospital, Sjöbergstiftelsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision cancer medicine with small tyrosine kinase inhibitors (TKIs) directed toward oncogenic drivers, are important treatment regimens for solid tumours. The epidermal growth factor receptor (EGFR)‐TKI osimertinib is a preferred therapy for patients with non‐small cell lung cancer (NSCLC) driven by activating mutations in EGFR , unfortunately responses are heterogeneous. This calls for non‐invasive methods to predict or monitor treatment response, for example, via biomarker analyses in blood. To reveal such putative biomarkers, we analysed the proteome of extracellular vesicles (EVs) from osimertinib resistant or responsive NSCLC cells in vitro and from EVs isolated from serum samples of NSCLC patients treated with osimertinib in second line within the phase II clinical trial TREM. The protein cargo of the EVs was analysed by mass spectrometry (MS) and proximity extension assay (PEA). Western blotting, ELISA and single vesicle analysis was performed to validate and further confirm the expression of certain proteins. MS profiling of the NSCLC cells and their released EVs revealed a protein signature associated with osimertinib refractoriness. Among them were CSPG4, HSPG2, MCAM, L1CAM, TAGLN, THBS1 and TNC. GO‐pathway analysis related several of these proteins to the focal adhesion and proteoglycan in cancer pathways. Some of these proteins, including CSPG4, which when suppressed by transient siRNA transfection in NSCLC cells resulted in reduced cell viability, were expressed also in EVs from serum of the NSCLC patients. Moreover, PEA profiling of the serum‐isolated EVs revealed signatures associated with immune cells, best response and/or progression‐free survival, including PD‐L1, CD73/NT5E, FR‐alpha/FOLR1, LAMP3, FASLG1 and ANXA1. In summary, we demonstrate that protein profiling of EVs in relation to osimertinib refractoriness has the potential to identify possible biomarkers that can indicate osimertinib treatment resistance, for example, CSPG4, HSPG2, TAGLN, TNC, THBS1, ANXA1 and CD73/NT5E. Studies in expanded cohorts should be conducted to further validate these putative osimertinib biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsDrug Resistance, NeoplasmExtracellular VesiclesHumansPyrimidinesIndolesCell Line, TumorBiomarkers, TumorFemaleProtein Kinase Inhibitors

Stichwörter der Autor:innen

biomarkersextracellular vesiclesmutant epidermal growth factor receptornon‐small cell lung cancerosimertinib

Substanzen

PyrimidinesAniline CompoundsIndolesosimertinibAcrylamidesBiomarkers, TumorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Dept of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Section of Oncology, Vestre Viken Hospital Trust, Drammen, Norway.
  • Dept of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Dept of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Dept of Applied Physics, School of Engineering Sciences, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Theme Cancer, Patient Area Head, Neck, Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Albano Cáceres-Verschae, Petra Hååg, Sofia Joelsson, Per Hydbring, Bo Franzén, Ákos Végvári, Inger Johanne Z Eide, Nupur Agarwal, Siddharth Sourabh Sahu, Fredrik Stridfeldt, Luigi De Petris, Apurba Dev, Simon Ekman, Odd Terje Brustugun, Rolf Lewensohn, Kristina Viktorsson

Förderung

  • Erling-Perssons Stiftelse
  • Forskning Utbildning och Utveckilng, Karolinska Hospital
  • Sjöbergstiftelsen
  • Cancerföreningen i Stockholm
  • Wellcome Trust
  • Vetenskapsrådet
  • Cancerfonden
  • Stiftelsen för Strategisk Forskning

Zitieren

APA

Cáceres-Verschae, A., Hååg, P., Joelsson, S., Hydbring, P., Franzén, B., Végvári, Á., Eide, I. J. Z., Agarwal, N., Sahu, S. S., Stridfeldt, F., De Petris, L., Dev, A., Ekman, S., Brustugun, O. T., Lewensohn, R., & Viktorsson, K. (2026). Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. Journal of Extracellular Vesicles, 15(1). https://doi.org/10.1002/jev2.70219

Vancouver

Cáceres-Verschae A, Hååg P, Joelsson S, Hydbring P, Franzén B, Végvári Á, et al. Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance. Journal of Extracellular Vesicles. 2026;15(1). doi:10.1002/jev2.70219

BibTeX
@article{CceresVerschae2026,
  author = {Cáceres-Verschae, Albano and Hååg, Petra and Joelsson, Sofia and Hydbring, Per and Franzén, Bo and Végvári, Ákos and Eide, Inger Johanne Z and Agarwal, Nupur and Sahu, Siddharth Sourabh and Stridfeldt, Fredrik and De Petris, Luigi and Dev, Apurba and Ekman, Simon and Brustugun, Odd Terje and Lewensohn, Rolf and Viktorsson, Kristina},
  title = {Profiling of Extracellular Vesicles of Non‐Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/jev2.70219}
}
Kostenlos starten →